Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 4
Submit an article Journal homepage
186
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Innate-like T cell profile in myeloma: Severe deficiency of Vγ9Vδ2 T cells in aminobisphosphonate-treated patients

Mairéad WalshHaematology Laboratory, Capital and Coast District Health Board, Wellington, New Zealand,
,
Glennis WhiteHaematology Laboratory, Capital and Coast District Health Board, Wellington, New Zealand,
,
Kenneth RomerilWellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand,
,
Huib BuyckWellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand,
,
Matthew StephensWellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand,
,
Collin BrooksMalaghan Institute of Medical Research, Wellington, New Zealand, ;Centre for Public Health Research, Massey University, Wellington, New Zealand, and
&
Robert WeinkoveWellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand, ;Malaghan Institute of Medical Research, Wellington, New Zealand, ;Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New ZealandCorrespondence[email protected]
 show all
Pages 977-980 | Received 15 Jul 2015, Accepted 24 Aug 2015, Published online: 09 Oct 2015

References

  • Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100: 107–113.
  • Tete SM, Bijl M, Sahota SS, et al. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol 2014; 5: 257.
  • Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563–579.
  • Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626–1629.
  • Kjer-Nielsen L, Patel O, Corbett AJ, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012; 491: 717–723.
  • Vavassori S, Kumar A, Wan GS, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol 2013; 14: 908–916.
  • Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31: 184–196.
  • Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003; 197: 1667–1676.
  • Nur H, Fostier K, Aspeslagh S, et al. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One 2013; 8: e65075.
  • Reantragoon R, Corbett AJ, Sakala IG, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med 2013; 210: 2305–2320.
  • Welton JL, Morgan MP, Marti S, et al. Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res 2013; 28: 464–471.
  • Kalyan S, Quabius ES, Wiltfang J, et al. Can peripheral blood gammadelta T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res 2013; 28: 728–735.
  • Chen ZW. Multifunctional immune responses of HMBPP-specific Vgamma2Vdelta2 T cells in M. tuberculosis and other infections. Cell Mol Immunol 2013; 10: 58–64.
  • Richter J, Neparidze N, Zhang L, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2012; 121: 423–430.
  • Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200–206.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.